Table 1.
Characteristics of Patients Undergoing First Autologous Transplant
| Characteristic | All Patients N = 620 |
|---|---|
| Age—yr | |
| Median | 57 |
| Range | 18–76 |
| Age, years | |
| ≤ 60 | 378 (61) |
| > 60 | 242 (39) |
| Sex, n (%) | |
| Female | 249 (40) |
| Male | 371 (60) |
| Race, n (%) | |
| Caucasian | 544 (88) |
| Black | 70 (11) |
| Other | 6 (1) |
| Diagnosis, n (%) | |
| Multiple Myeloma | 361 (58) |
| Hodgkins Disease | 80 (13) |
| Diffuse Large B-Cell Lymphoma | 96 (15) |
| Follicular Lymphoma | 8 (1) |
| Mantle Cell Lymphoma | 55 (9) |
| Other Lymphoma | 20 (3) |
| Karnofsky Performance Status | |
| Median | 90 |
| Range | 50–100 |
| Karnofsky Performance Status, n (%) | |
| 50 | 1 (<1) |
| 60 | 4 (<1) |
| 70 | 38 (6) |
| 80 | 202 (33) |
| 90 | 273 (44) |
| 100 | 102 (16) |
| Transplant Comorbidity Index | |
| Median | 2 |
| Range | 0–10 |
| Transplant Comorbidity Index, n (%) | |
| 0 | 109 (18) |
| 1 | 80 (13) |
| 2 | 157 (25) |
| 3 | 132 (21) |
| 4 | 71 (11) |
| 5 | 42 (7) |
| 6 | 16 (3) |
| 7 | 7 (1) |
| 8 | 4 (<1) |
| 9 | 1 (<1) |
| 10 | 1 (<1) |
| Number of Prior Treatments | |
| Median | 1 |
| Range | 0–6 |
| Pre-Transplant Response Status, n (%) | |
| SD/PD | 58 (9) |
| CR/PR | 562 (91) |
| Conditioning, n (%) | |
| Melphalan | 360 (58) |
| BEAM | 241 (39) |
| BEC | 18 (3) |
| Other | 1 (0.2) |
| Mobilization, n (%) | |
| G-CSF | 293 (47) |
| Plerixafor | 196 (32) |
| E | 32 (5) |
| G-CSF+Chemo | 81 (13) |
| G-CSF+Plerixafor+Chemo | 18 (3) |
| Radiation Received, n (%) | |
| No | 485 (78) |
| Yes | 135 (22) |
| CD34 Dose | |
| Median (in millions of cells per kilogram) | 4.36 |
| Range | 1.27–53.68 |
| ANC Recovery Time, days | |
| Median | 10 |
| Range | 8–19 |
| Platelet Recovery Time, days | |
| Median | 18 |
| Range | 0–59 |
| Length of Stay, days | |
| Median | 17 |
| Range | 11–57 |
Abbreviations: EAR: Etoposide, cytarabine, and rituximab; ANC: Absolute neutrophil count